title: Biologics in rheumatoid arthritis: where are we going?
abstract: Biological disease-modifying antirheumatic drugs have significantly improved outcomes for patients with rheumatoid arthritis, but cost limits their use. This article assesses data on patients who have achieved remission or low disease activity with these drugs and the possibility of dose reduction or discontinuation in these patients.
authors.affiliation: Visiting Fellow.
authors.forename: Marie
authors.initials: M
authors.lastname: Fechtenbaum
authors.forename: Jackie L
authors.initials: JL
authors.lastname: Nam
authors.forename: Paul
authors.initials: P
authors.lastname: Emery
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D001688:Biological Products / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products; D007155:Immunologic Factors